Harrow Health Inc (HROW)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
HROW
Harrow Health Inc
$29.37
-3.64%
HEALTHCARE · Cap: $1.10B
TAK
Takeda Pharmaceutical Co Ltd ADR
$21.12
+1.34%
HEALTHCARE · Cap: $67.16B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 1547530% more annual revenue ($4.69T vs $303.25M). TAK leads profitability with a 0.9% profit margin vs -9.4%. TAK earns a higher WallStSmart Score of 56/100 (C).
HROW
Hold40
out of 100
Grade: F
TAK
Buy56
out of 100
Grade: C
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 38.6% year-over-year
Earnings expanding 810.0% YoY
Growing faster than its price suggests
Reasonable price relative to book value
Generating 212.6B in free cash flow
Large-cap with strong market position
Strong operational efficiency at 24.5%
Areas to Watch
Smaller company, higher risk/reward
Trading at 38.1x book value
ROE of -35.4% — below average capital efficiency
Negative free cash flow — burning cash
ROE of 5.2% — below average capital efficiency
0.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 9.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : HROW
The strongest argument for HROW centers on Revenue Growth, EPS Growth. Revenue growth of 38.6% demonstrates continued momentum.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, Free Cash Flow. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bear Case : HROW
The primary concerns for HROW are Market Cap, Price/Book, Return on Equity. Debt-to-equity of 19.79 is elevated, increasing financial risk.
Bear Case : TAK
The primary concerns for TAK are Return on Equity, Profit Margin, P/E Ratio. A P/E of 300.3x leaves little room for execution misses. Thin 0.9% margins leave little buffer for downturns.
Key Dynamics to Monitor
HROW profiles as a hypergrowth stock while TAK is a value play — different risk/reward profiles.
HROW carries more volatility with a beta of 0.17 — expect wider price swings.
HROW is growing revenue faster at 38.6% — sustainability is the question.
TAK generates stronger free cash flow (212.6B), providing more financial flexibility.
Bottom Line
TAK scores higher overall (56/100 vs 40/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Harrow Health Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Harrow Health, Inc. is an ophthalmology-focused healthcare company. The company is headquartered in San Diego, California.
Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?